Condoms associated with moderate protection against herpes simplex virus 2

Jul 13, 2009

Condom use is associated with a reduced risk of contracting herpes simplex virus 2, according to a report based on pooled analysis of data from previous studies in the July 13 issue of Archives of Internal Medicine.

Herpes simplex virus 2 () typically causes genital , a chronic, life-long, viral infection. Although studies indicate that consistent condom use reduces the spread of HIV and other sexually transmitted diseases such as and gonorrhea, the effectiveness of preventing the transmission of HSV-2 through condom use is less certain, according to background information in the article.

Emily T. Martin, M.P.H., Ph.D., of Children's Hospital Research Institute and the University of Washington, Seattle, and colleagues analyzed data from six HSV-2 studies to assess the effectiveness of condom use in preventing the virus. The studies included three candidate HSV-2 vaccine studies, an HSV-2 drug study, an observational sexually transmitted infection (STI) incidence study and a behavioral STI intervention study. These yielded results from 5,384 HSV-2-negative individuals (average age 29) at baseline for a combined total of 2,040,894 follow-up days.

More than 66 percent of those who took part in the six studies were male, 60.4 percent were white, 94.1 percent were heterosexual and most reported no prior STIs.

A total of 415 of the individuals acquired HSV-2 during follow-up. "Consistent condom users [used 100 percent of the time] had a 30 percent lower risk of HSV-2 acquisition compared with those who never used condoms," the authors write. "Risk of HSV-2 acquisition decreased by 7 percent for every additional 25 percent of the time that condoms were used during anal or vaginal sex." The risk of acquiring the virus increased significantly with increasing frequency of acts. There were no significant differences found in condom effectiveness between men and women.

"Based on findings of this large analysis using all available prospective data, use should continue to be recommended to both men and women for reducing the risk of HSV-2 acquisition," the authors conclude. "Although the magnitude of the protective effect was not as large as has been observed with other STIs, a 30 percent reduction in HSV-2 incidence can have a substantial benefit for individuals as well as a public health impact at the population level."

More information: Arch Intern Med. 2009;169[13]:1233-1240.

Source: JAMA and Archives Journals (news : web)

Explore further: Long wait yet for Ebola vaccine: experts

add to favorites email to friend print save as pdf

Related Stories

Herpes on the rise in Australia

May 19, 2006

One in eight Australian adults has been infected with the virus causing genital herpes, with the rate one in five for women aged 35-44, a study said.

Herpes drug inhibits HIV replication, but with a price

Nov 06, 2008

The anti-herpes drug acyclovir can also directly slow down HIV infection by targeting the reverse transcriptase (RT) enzyme, researchers report in this week's JBC. This beneficial effect does pose a risk though, as HIV-in ...

Researchers identify how herpes virus infects host cells

Mar 26, 2008

Virginia Commonwealth University researchers have uncovered new information about how the herpes simplex virus takes control of the host cell, setting the stage for the development of antiviral drugs that serve to fight herpes ...

Recommended for you

Long wait yet for Ebola vaccine: experts

9 minutes ago

It will be months, at least, before a vaccine becomes available to tackle Ebola, experts said Thursday as researchers reported success in early, safety tests with a leading candidate.

Sierra Leone to miss target for beating Ebola: UN

1 hour ago

The United Nations' Ebola response mission admitted Thursday it was going to miss its target for beating the deadly epidemic in Sierra Leone due to a chronic shortage of hospital beds.

Global Ebola toll rises to 5,689: WHO

5 hours ago

The World Health Organization said Thursday that the global death toll from the Ebola virus had increased to 5,689 out of a total of 15,935 cases of infection, mainly in western Africa.

Ebola vaccine promising in first human trials

16 hours ago

Researchers say they're a step closer to developing an Ebola vaccine, with a Phase 1 trial showing promising results, but it will be months at the earliest before it can be used in the field.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.